期刊文献+

乳腺癌TOP2A基因与蒽环类药物疗效及患者预后关系研究进展 预览

A Literature Review of TOP2A Gene as A Predictive Marker of Anthracycline Efficacy and Prognosis of Patients with Breast Cancer
在线阅读 下载PDF
收藏 分享 导出
摘要 蒽环类药物在乳腺癌新辅助化疗和辅助化疗中占据着重要地位。作为蒽环类药物作用靶点,拓扑异构酶Ⅱα(TOP2A)能否作为预测蒽环类药物疗效的生物标志物激发了人们的研究兴趣。从TOP2A基因、RNA、蛋白表达三个水平分析TOP2A对蒽环类药物疗效的预测价值,并探讨TOP2A与乳腺癌患者预后的关系。 Anthracyclines occupies an important position in the neoadjuvant and adjuvant chemotherapy for breast cancer treatment. As the molecular target of Anthracyclines, whether TOP2A can act as a reliable biomarker predictive of chemosensitivity in breast cancer patients treated with anthracyclines has excited considerable interest in research. This review focuses on the predictive value of TOP2A for anthracycline efficacy and its impact on the prognosis of patients with breast cancer at three different levels of gene status, mRNA and protein expression.
作者 陈富龙 王坤 CHEN Fu-long1,2, WANG Kun2 ( 1. Shantou University Medical College, Guangdong Shantou 515041, China ; 2. Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China)
出处 《循证医学》 CSCD 2016年第4期247-252,共6页 The Journal of Evidence-Based Medicine
关键词 乳腺癌 TOP2A基因 蒽环类药物 疗效 预后 breast cancer TOP2A gene anthracyclines efficacy prognosis
作者简介 陈富龙(1990-),男,广东湛江人,硕士研究生,从事TOP2A基因与乳腺癌蒽环类药物疗效关系的研究。 [通讯作者]王坤,Tel:020-87551296;E-mail:gzwangkun@126.com
  • 相关文献

参考文献43

  • 1Menna P, Paz OG, Chello M, et al. Anthracycline cardiotoxicity[J]. Expert Opin Drug Saf, 2012,11( Suppl 1):S21-S36. 被引量:1
  • 2Bartlett JM, Mcconkey CC, Munro AF, et al. Predicting anthracycline benefit: TOP2A and CEP17-Not only but also[J]. J Clin Oncol, 2015,33(15):1680-1687. 被引量:1
  • 3Uemura T, Ohkura H, Adachi Y, et al. DNA Topoisomerase Ⅱ is required for condensation and separation of mitotic chromosomes in S. pombe[J]. Cell, 1987,50(6):917-925. 被引量:1
  • 4Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA Topoisomerase Ⅱ in normal and neoplastic human tissues[J]. Br J Cancer, 1997,75(9):1340-1346. 被引量:1
  • 5Bouchalova K, Cizkova M, Cwiertka K, et al. Triple negative breast cancer—current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2009,153(1):13-17. 被引量:1
  • 6Lamy PJ, Fina F, Bascoul-Mollevi C, et al. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers[J]. Breast Cancer Res, 2011,13(1):R15. 被引量:1
  • 7Brase JC, Schmidt M, Fischbach T, et al. ERBB2 and TOP2A in breast cancer: A comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction[J]. Clin Cancer Res, 2010, 16(8):2391-2401. 被引量:1
  • 8Fountzilas G, Valavanis C, Kotoula V, et al. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy[J]. J Transl Med, 2012, 10:10. 被引量:1
  • 9Ravid A, Rocker D, Machlenkin A, et al. 1,25- Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to Doxorubicin-induced oxidative damage[J]. Cancer Res, 1999, 59(4):862-867. 被引量:1
  • 10Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase Ⅱ[J]. Science, 1984,226(4673):466-468. 被引量:1

二级参考文献20

  • 1曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量:62
  • 2王莉萍,沈坤炜,沈镇宙.赫赛汀在乳腺癌新辅助治疗与辅助治疗中的新进展[J].中华肿瘤杂志,2006,28(4):241-243. 被引量:24
  • 3杨丽芳,宋三泰,李晓兵,江泽飞,刘晓晴,马维娜,乔西平,郭斯启.284例原发乳腺癌c—erbB2蛋白的表达及其与预后的关系[J].中华肿瘤杂志,2006,28(4):294-297. 被引量:9
  • 4乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:143
  • 5Brase JC,Schmidt M,Fischbach T,et al.ERBB2 and T0P2A in breast cancer;a comprehensive analysis of gene amplification RNA levels and protein expression and their influence on prognosis and prediction.Clin Cancer Res,2010,16:2391-2401. 被引量:1
  • 6Kwon HC,Roh MS,Oh SY,et al.Prognostic value of expression of ERCCI,thymidylate synthase,and ghtathione S-tramferase PI for 5-fluomuraeil/oxaliplalin chemotherapy in advanced gastric cancer.Ann Oncol,2007,18:504-509. 被引量:1
  • 7Jarvinen TA,Tanner M,Rantanen V,et al.Amplification and deletion of topoisomerase Ⅱ alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase Ⅱ inhibitor doxorubicin in breast cancer.Am J Pathol,2000,156:839-847. 被引量:1
  • 8Orlando L,Del Curto B,Gandini S,et al.Topoisomerase Ⅱ alpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.Breast,2008,17:506-511. 被引量:1
  • 9Tanner M,Isola J,Wiklund T,et al.Topoisomerase Ⅱ alpha gene amplification predicts favorable treatment response to tailored and Jose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:Scandinavian Breast Group Trial 9401.J Clin Oncol,2006,24:2428-2436. 被引量:1
  • 10Bhargava R,Lai P,Chen B.HER-2/neu and topoisomerase Ⅱ alpha gene amplification and protein expression in invasive breast carcinomas; chromogenic in situ hybridization and immunohistochemical analyses.Am J Clin Pathol,2005,123:889-895. 被引量:1

共引文献3

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏